On Friday, NanoRepro published its H1 26 single-entity report, provided a commercial update on newkee and set a new timeline for its outstanding consolidated reports. The key takeaways are stronger-than-expected Paedi Protect sales, continued cost savings at holding level and a first drugstore listing for newkee, which underlines the progress of the platform strategy.
LÄS MER
